Table 2 Characteristics of GLP-1 receptor agonist cases reporting male sexual dysfunction adverse events in FAERS.
VARIABLES | N (%) | |
|---|---|---|
DRUG NAME | Brand name | |
DULAGLUTIDE | TRULICITY | 17 |
DULAGLUTIDEa | 17 | |
DULAGLUTIDE TOTAL | 34 (18.7%) | |
EXENATIDE | BYDUREON | 4 |
BYETTA | 35 | |
BYDUREON BCISE | 1 | |
EXENATIDEa | 4 | |
EXENATIDE TOTAL | 44 (24.2%) | |
LIRAGLUTIDE | VICTOZA | 22 |
SAXENDA | 1 | |
LIRAGLUTIDEa | 15 | |
LIRAGLUTIDE TOTAL | 38 (20.9%) | |
LIXISENATIDE | LYXUMIA | 1 |
LIXISENATIDE TOTAL | 1 (0.5%) | |
SEMAGLUTIDE | OZEMPIC | 27 |
RYBELSUS | 3 | |
SEMAGLUTIDEa | 9 | |
SEMAGLUTIDE TOTAL | 39 (21.4%) | |
TIRZEPATIDE | MOUNJARO | 14 |
TIRZEPATIDEa | 12 | |
TIRZEPATIDE TOTAL | 26 (14.3%) | |
AGE GROUP | Under 20 | 0 (0%) |
21–30 | 2 (1/1%) | |
31–40 | 5 (2.7%) | |
41–50 | 30 (16.5%) | |
51–60 | 36 (19.8%) | |
61–70 | 27 (14.8%) | |
70+ | 10 (5.5%) | |
Unknown | 71 (39.0%) | |
REPORTER COUNTRY | United States | 160 (87.9%) |
European countries | 15 (8.2%) | |
China | 2 (1.1%) | |
Mexico | 1 (0.5%) | |
Canada | 1 (0.5%) | |
Israel | 1 (0.5%) | |
Japan | 1 (0.5%) | |
Lebanon | 1 (0.5%) | |
LEVEL OF THE SUSPECT DRUG | Primary Suspect Drug | 144 (79.1%) |
Concomitant | 28 (15.4%) | |
Secondary Suspect Drug | 10 (5.5%) | |
ROUTES OF ADMINISTRATION | Subcutaneous | 102 (56.0%) |
Oral | 3 (1.6%) | |
Unknown | 77 (42.3%) | |
GRAND TOTAL | 182 |
